| Event/Highlight | Details |
|---|---|
| Initiative Launch | Servier India launches a national initiative to improve access to biomarker testing for Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA). |
| Partnerships | Collaborates with MedGenome and Strand Life Sciences for genomic testing and diagnostics. |
| Focus | Aims to enhance access to precision oncology tools, especially in public healthcare and underserved areas. |
| Key Genetic Markers | Focuses on IDH1 and IDH2 mutations, critical for targeted therapy in AML and CCA. |
| Cost Coverage | Free biomarker testing for patients in government hospitals; subsidised rates for others under patient-assistance programmes. |
| Cancer Types | Acute Myeloid Leukaemia (AML)--blood cancer affecting white blood cells; Cholangiocarcinoma (CCA)--rare bile duct cancer. |
| Precision Oncology | Treatment tailored to individual cancer genetics, improving efficacy and patient outcomes. |
| Collaborative Model | Partnerships with genomic labs, clinicians, hospitals, and patient networks for last-mile delivery of diagnostics and treatment. |
| Servier Care Initiative | Provides free/subsidised diagnostics, financial support, medication access, and treatment guidance for patients. |
| Objective | To bridge the gap in molecular diagnostics availability in tier-2 and tier-3 cities, ensuring equitable access. |
Workflow
Login
Contact Counsellor